Developing Transformative Precision Immunotherapies
THE MOST COMPREHENSIVE T CELL TARGETING PLATFORM IN THE INDUSTRY
Patients diagnosed with solid cancers or autoimmune diseases often have limited and ineffective treatment options.
By understanding how the immune system recognizes, targets and destroys cancer cells, 3T’s technology is advancing the development of next-generation therapies that have the potential to be safer and more effective for these difficult-to-treat cancers.
Starting with a productive response from patients, we can identify shared targets and therapeutically active T cell receptors (TCR) and T cell receptor mimetics (TCRm). These novel targets and therapeutics can enable development of highly specific, safer and more effective cancer treatments.